View in EDS HTML Full Text PDF Full Text

Targeting Bruton tyrosine kinase with acalabrutinib attenuates murine sclerodermatous chronic graft versus host disease.

Saved in:
Bibliographic Details
Title: Targeting Bruton tyrosine kinase with acalabrutinib attenuates murine sclerodermatous chronic graft versus host disease.
Authors: Raguraman V; Division of Hematology and Medical Oncology, Department of Medicine, Ellis Fischel Cancer Center, University of Missouri, Columbia, MO, United States., Mysinger M; Division of Hematology & Blood and Marrow Transplantation, Department of Internal Medicine, Markey Cancer Center, University of Kentucky, Lexington, KY, United States., Verma M; Department of Biomedical Sciences, Joan C. Edwards School of Medicine, Marshall University, Huntington, WV, United States., Mohiyuddin S; Division of Hematology and Medical Oncology, Department of Medicine, Ellis Fischel Cancer Center, University of Missouri, Columbia, MO, United States., Jabbour N; Department of Pathology and Laboratory Medicine, University of Kentucky, Lexington, KY, United States., Kesler M; Department of Pathology and Laboratory Medicine, University of Kentucky, Lexington, KY, United States., Joshi T; Department of Biomedical Sciences, Joan C. Edwards School of Medicine, Marshall University, Huntington, WV, United States.; Department of Biomedical Informatics, Biostatistics and Medical Epidemiology, University of Missouri, Columbia, MO, United States., Palaniyandi S; Division of Hematology and Medical Oncology, Department of Medicine, Ellis Fischel Cancer Center, University of Missouri, Columbia, MO, United States.; Division of Hematology & Blood and Marrow Transplantation, Department of Internal Medicine, Markey Cancer Center, University of Kentucky, Lexington, KY, United States., Hildebrandt GC; Division of Hematology and Medical Oncology, Department of Medicine, Ellis Fischel Cancer Center, University of Missouri, Columbia, MO, United States.; Division of Hematology & Blood and Marrow Transplantation, Department of Internal Medicine, Markey Cancer Center, University of Kentucky, Lexington, KY, United States.
Source: Frontiers in immunology [Front Immunol] 2026 Jun 11; Vol. 17, pp. 1843217. Date of Electronic Publication: 2026 Jun 11 (Print Publication: 2026).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42367798
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Targeting Bruton tyrosine kinase with acalabrutinib attenuates murine sclerodermatous chronic graft versus host disease.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Raguraman+V%22">Raguraman V</searchLink>; Division of Hematology and Medical Oncology, Department of Medicine, Ellis Fischel Cancer Center, University of Missouri, Columbia, MO, United States.<br /><searchLink fieldCode="AU" term="%22Mysinger+M%22">Mysinger M</searchLink>; Division of Hematology & Blood and Marrow Transplantation, Department of Internal Medicine, Markey Cancer Center, University of Kentucky, Lexington, KY, United States.<br /><searchLink fieldCode="AU" term="%22Verma+M%22">Verma M</searchLink>; Department of Biomedical Sciences, Joan C. Edwards School of Medicine, Marshall University, Huntington, WV, United States.<br /><searchLink fieldCode="AU" term="%22Mohiyuddin+S%22">Mohiyuddin S</searchLink>; Division of Hematology and Medical Oncology, Department of Medicine, Ellis Fischel Cancer Center, University of Missouri, Columbia, MO, United States.<br /><searchLink fieldCode="AU" term="%22Jabbour+N%22">Jabbour N</searchLink>; Department of Pathology and Laboratory Medicine, University of Kentucky, Lexington, KY, United States.<br /><searchLink fieldCode="AU" term="%22Kesler+M%22">Kesler M</searchLink>; Department of Pathology and Laboratory Medicine, University of Kentucky, Lexington, KY, United States.<br /><searchLink fieldCode="AU" term="%22Joshi+T%22">Joshi T</searchLink>; Department of Biomedical Sciences, Joan C. Edwards School of Medicine, Marshall University, Huntington, WV, United States.; Department of Biomedical Informatics, Biostatistics and Medical Epidemiology, University of Missouri, Columbia, MO, United States.<br /><searchLink fieldCode="AU" term="%22Palaniyandi+S%22">Palaniyandi S</searchLink>; Division of Hematology and Medical Oncology, Department of Medicine, Ellis Fischel Cancer Center, University of Missouri, Columbia, MO, United States.; Division of Hematology & Blood and Marrow Transplantation, Department of Internal Medicine, Markey Cancer Center, University of Kentucky, Lexington, KY, United States.<br /><searchLink fieldCode="AU" term="%22Hildebrandt+GC%22">Hildebrandt GC</searchLink>; Division of Hematology and Medical Oncology, Department of Medicine, Ellis Fischel Cancer Center, University of Missouri, Columbia, MO, United States.; Division of Hematology & Blood and Marrow Transplantation, Department of Internal Medicine, Markey Cancer Center, University of Kentucky, Lexington, KY, United States.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101560960%22">Frontiers in immunology</searchLink> [Front Immunol] 2026 Jun 11; Vol. 17, pp. 1843217. <i>Date of Electronic Publication: </i>2026 Jun 11 (<i>Print Publication: </i>2026).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101560960 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>1664-3224 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2216643224%22">16643224 </searchLink><i>NLM ISO Abbreviation: </i>Front Immunol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42367798
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fimmu.2026.1843217
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1843217
    Titles:
      – TitleFull: Targeting Bruton tyrosine kinase with acalabrutinib attenuates murine sclerodermatous chronic graft versus host disease.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Raguraman V
      – PersonEntity:
          Name:
            NameFull: Mysinger M
      – PersonEntity:
          Name:
            NameFull: Verma M
      – PersonEntity:
          Name:
            NameFull: Mohiyuddin S
      – PersonEntity:
          Name:
            NameFull: Jabbour N
      – PersonEntity:
          Name:
            NameFull: Kesler M
      – PersonEntity:
          Name:
            NameFull: Joshi T
      – PersonEntity:
          Name:
            NameFull: Palaniyandi S
      – PersonEntity:
          Name:
            NameFull: Hildebrandt GC
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 11
              M: 06
              Text: 2026 Jun 11
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1664-3224
          Numbering:
            – Type: volume
              Value: 17
          Titles:
            – TitleFull: Frontiers in immunology
              Type: main
ResultId 1